首页 | 本学科首页   官方微博 | 高级检索  
     


Nutrition in adult patients with selected lysosomal storage diseases
Authors:Francesca Carubbi  Antonio Barbato  Alberto B. Burlina  Francesco Francini  Renzo Mignani  Elena Pegoraro  Linda Landini  Gianluca De Danieli  Stefano Bruni  Pasquale Strazzullo
Affiliation:1. U.O.C. Medicina metabolica AOU Modena, Metabolic Medicine Unit, Modena University Hospital, Modena, Italy;2. Department of Clinical Medicine and Surgery, “Federico II” University Hospital, Naples, Italy;3. U.O.C. Malattie Metaboliche Ereditarie, Major Operational Unit of Hereditary Metabolic Diseases, Azienda Ospedaliera di Padova, Padua, Italy;4. U.O. Nutrizione Clinica, Department of Medicine, Azienda Ospedaliera di Padova, Padua, Italy;5. U.O. di Nefrologia e Dialisi dell''Ospedale Infermi di Rimini, Nephrology Operational Unit of the Infermi Hospital in Rimini, Rimini, Italy;6. Department of Neuroscience, University of Padova, Padua, Italy;7. Sanofi Italia, Milan, Italy;8. S.S.D. Dietetics and Clinical Nutrition ASL 4 Chiavarese Liguria – Sestri Levante Hospital, Italy
Abstract:
Lysosomal storage disorders (LSDs) are a group of clinically heterogeneous disorders affecting the function of lysosomes and are characterized by an accumulation of undigested substrates within several cell types. In recent years there have been substantial advances in supportive care and drug treatment for some LSDs, leading to improved patient survival, as seen in Gaucher, Pompe and Fabry disease and some Mucopolysaccharidoses; however, many symptoms still persist. Thus it is now even more important to improve patients' quality of life and reduce symptoms and comorbidities. One potential way of achieving this goal is through adjunct nutritional therapy, which is challenging as patients may be overweight with associated consequences, or malnourished, or underweight. Furthermore, drugs used to treat LSDs can modify the metabolic status and needs of patients. There are currently not enough data to make specific dietary recommendations for individual LSDs; however, suggestions can be made for managing clinical manifestations of the diseases, as well as treatment-associated adverse events. The metabolic and nutritional status of adult patients must be regularly assessed and individualized dietary plans may be created to cater to a patient's specific needs. Damage to the autophagic process is a common feature in LSDs that is potentially sensitive to dietary manipulation and needs to be assessed in clinical studies.
Keywords:Dietary modifications  Lysosomal storage disorders  Nutrition therapy  Recommendations  AEs"  },{"  #name"  :"  keyword"  ,"  $"  :{"  id"  :"  kwrd0035"  },"  $$"  :[{"  #name"  :"  text"  ,"  _"  :"  adverse events  ASM"  },{"  #name"  :"  keyword"  ,"  $"  :{"  id"  :"  kwrd0045"  },"  $$"  :[{"  #name"  :"  text"  ,"  _"  :"  acid sphingomyelinase  ASMD"  },{"  #name"  :"  keyword"  ,"  $"  :{"  id"  :"  kwrd0055"  },"  $$"  :[{"  #name"  :"  text"  ,"  _"  :"  acid sphingomyelinase deficiency  BMD"  },{"  #name"  :"  keyword"  ,"  $"  :{"  id"  :"  kwrd0065"  },"  $$"  :[{"  #name"  :"  text"  ,"  _"  :"  bone mineral density  CKD"  },{"  #name"  :"  keyword"  ,"  $"  :{"  id"  :"  kwrd0075"  },"  $$"  :[{"  #name"  :"  text"  ,"  _"  :"  chronic kidney disease  CoQ10"  },{"  #name"  :"  keyword"  ,"  $"  :{"  id"  :"  kwrd0085"  },"  $$"  :[{"  #name"  :"  text"  ,"  _"  :"  Coenzyme Q10  CYP"  },{"  #name"  :"  keyword"  ,"  $"  :{"  id"  :"  kwrd0095"  },"  $$"  :[{"  #name"  :"  text"  ,"  _"  :"  cytochrome P450  DXA"  },{"  #name"  :"  keyword"  ,"  $"  :{"  id"  :"  kwrd0105"  },"  $$"  :[{"  #name"  :"  text"  ,"  _"  :"  dual-energy X-ray absorptiometry  ERT"  },{"  #name"  :"  keyword"  ,"  $"  :{"  id"  :"  kwrd0115"  },"  $$"  :[{"  #name"  :"  text"  ,"  _"  :"  enzyme replacement therapy  FD"  },{"  #name"  :"  keyword"  ,"  $"  :{"  id"  :"  kwrd0125"  },"  $$"  :[{"  #name"  :"  text"  ,"  _"  :"  Fabry disease  FODMAP"  },{"  #name"  :"  keyword"  ,"  $"  :{"  id"  :"  kwrd0135"  },"  $$"  :[{"  #name"  :"  text"  ,"  _"  :"  fermentable oligosaccharide, disaccharide, monosaccharide and polyol  GAA"  },{"  #name"  :"  keyword"  ,"  $"  :{"  id"  :"  kwrd0145"  },"  $$"  :[{"  #name"  :"  text"  ,"  _"  :"  acid alpha glucosidase  GD"  },{"  #name"  :"  keyword"  ,"  $"  :{"  id"  :"  kwrd0155"  },"  $$"  :[{"  #name"  :"  text"  ,"  _"  :"  Gaucher disease  HDL"  },{"  #name"  :"  keyword"  ,"  $"  :{"  id"  :"  kwrd0165"  },"  $$"  :[{"  #name"  :"  text"  ,"  _"  :"  high-density lipoprotein  HOMA"  },{"  #name"  :"  keyword"  ,"  $"  :{"  id"  :"  kwrd0175"  },"  $$"  :[{"  #name"  :"  text"  ,"  _"  :"  homeostatic model assessment  HSCT"  },{"  #name"  :"  keyword"  ,"  $"  :{"  id"  :"  kwrd0185"  },"  $$"  :[{"  #name"  :"  text"  ,"  _"  :"  hematopoietic stem cell transplantation  LSDs"  },{"  #name"  :"  keyword"  ,"  $"  :{"  id"  :"  kwrd0195"  },"  $$"  :[{"  #name"  :"  text"  ,"  _"  :"  lysosomal storage diseases  MPS"  },{"  #name"  :"  keyword"  ,"  $"  :{"  id"  :"  kwrd0205"  },"  $$"  :[{"  #name"  :"  text"  ,"  _"  :"  mucopolysaccharidoses  mTOR"  },{"  #name"  :"  keyword"  ,"  $"  :{"  id"  :"  kwrd0215"  },"  $$"  :[{"  #name"  :"  text"  ,"  _"  :"  mammalian target of rapamycin complex 1  NPD-A"  },{"  #name"  :"  keyword"  ,"  $"  :{"  id"  :"  kwrd0225"  },"  $$"  :[{"  #name"  :"  text"  ,"  _"  :"  Niemann-Pick disease type A  NPD-B"  },{"  #name"  :"  keyword"  ,"  $"  :{"  id"  :"  kwrd0235"  },"  $$"  :[{"  #name"  :"  text"  ,"  _"  :"  Niemann-Pick disease type B  NPD-C"  },{"  #name"  :"  keyword"  ,"  $"  :{"  id"  :"  kwrd0245"  },"  $$"  :[{"  #name"  :"  text"  ,"  _"  :"  Niemann-Pick disease type C  PD"  },{"  #name"  :"  keyword"  ,"  $"  :{"  id"  :"  kwrd0255"  },"  $$"  :[{"  #name"  :"  text"  ,"  _"  :"  Pompe disease (Glycogen storage type II disease)  PLP"  },{"  #name"  :"  keyword"  ,"  $"  :{"  id"  :"  kwrd0265"  },"  $$"  :[{"  #name"  :"  text"  ,"  _"  :"  pyridoxal phosphate  sphingomyelin phosphodiesterase 1 gene  SRT"  },{"  #name"  :"  keyword"  ,"  $"  :{"  id"  :"  kwrd0285"  },"  $$"  :[{"  #name"  :"  text"  ,"  _"  :"  substrate reduction therapy
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号